cobalt tetracemate Report issue

Small molecule Experimental
ChEMBL MeSH PubChem

Active Ingredient History

Dicobalt edetate was developed as a cyanide antidote based on the known ability of cobalt to form stable complexes with cyanide. One current cobalt-based antidote available in Europe is dicobalt-EDTA, sold as Kelocyanor. This agent chelates cyanide as the cobalticyanide. This drug provides an antidote effect more quickly than formation of methemoglobin. It can be very toxic and cause seizures, upper airway oedema, chest pain, hypotension, vomiting, rashes and dyspnoea especially in those who have not be exposed to cyanide.   NCATS

Chemistry

  • SMILES: [Co++].[Co++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
  • InChIKey: TWAWHTJKASJPEK-UHFFFAOYSA-J
  • Mol. Mass: 406.0773
  • ALogP: Missing data
  • ChEMBL Molecule:
    dicobalt edetate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

cobalt-edta complex | cobalt-ethylenediamine tetraacetic acid chelate | cobalt-ethylenediamine tetraacetic acid chelate, disodium salt | cobalt tetracemate | dicobalt edetate | edta-cobalt chelate | kelocyanor

Indications (3)

Approved Indications (2)


 

Helminthiasis

Poisoning

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Anemia ()

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue